Medpace (NASDAQ:MEDP) & Eurofins Scient (OTCMKTS:ERFSF) Financial Review

Eurofins Scient (OTCMKTS:ERFSF) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares Eurofins Scient and Medpace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eurofins Scient	N/A	N/A	N/A
Medpace	17.83%	118.82%	25.07%

Insider & Institutional Ownership

78.0% of Medpace shares are held by institutional investors. 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Eurofins Scient and Medpace, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eurofins Scient	0	3	1	0	2.25
Medpace	1	9	5	0	2.27

Medpace has a consensus price target of $486.67, suggesting a potential upside of 1.70%. Given Medpace’s stronger consensus rating and higher probable upside, analysts plainly believe Medpace is more favorable than Eurofins Scient.

Valuation and Earnings

This table compares Eurofins Scient and Medpace”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eurofins Scient	$8.25 billion	1.72	$537.29 million	N/A	N/A
Medpace	$2.53 billion	5.37	$451.12 million	$15.30	31.28

Eurofins Scient has higher revenue and earnings than Medpace.

Risk and Volatility

Eurofins Scient has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.

Summary

Medpace beats Eurofins Scient on 10 of the 12 factors compared between the two stocks.

About Eurofins Scient

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.